ZyStor Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $35.9M

ZyStor Therapeutics General Information

Description

Developer of replacement therapies for lysosomal storage disease. The company develops enzyme replacement technologies which improve the delivery of therapeutics that replace the missing lysosomal enzyme for the treatment of patients who suffer from genetic disorders known as lysosomal storage diseases.

Contact Information

Website
www.zystor.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 10437 West Innovation Drive
  • Suite 100
  • Wauwatosa, WI 53226
  • United States
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
BioMarin Pharmaceutical
Vertical(s)
Life Sciences
Corporate Office
  • 10437 West Innovation Drive
  • Suite 100
  • Wauwatosa, WI 53226
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ZyStor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 17-Aug-2010 $35.9M Completed Generating Revenue
5. Later Stage VC 25-Jun-2010 Completed Generating Revenue
4. Early Stage VC 28-Aug-2008 Completed Startup
3. Early Stage VC 17-May-2007 Completed Startup
2. Early Stage VC 21-Dec-2005 $8.5M Completed Startup
1. Early Stage VC 15-Dec-2004 $8.5M $8.5M Completed Startup
To view ZyStor Therapeutics’s complete valuation and funding history, request access »

ZyStor Therapeutics Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

ZyStor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20120148556-A1 Formulations for lysosomal enzymes Active 17-Jun-2009
US-8785168-B2 Formulations for lysosomal enzymes Active 17-Jun-2009
US-20110223147-A1 Lysosomal targeting peptides and uses thereof Inactive 07-May-2008
DE-602005020745-D1 Acid alpha-glucosidase and fragments thereof Inactive 10-Feb-2004
EP-1716232-A2 Acid alpha-glucosidase and fragments thereof Active 10-Feb-2004 A61K38/47
To view ZyStor Therapeutics’s complete patent history, request access »

ZyStor Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ZyStor Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apjohn Ventures Venture Capital Minority
Hexagon (Denver) Asset Manager Minority
Keane D'Souza Venture Capital Venture Capital Minority
Mason Wells PE/Buyout Minority
Prolog Ventures Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

ZyStor Therapeutics FAQs

  • When was ZyStor Therapeutics founded?

    ZyStor Therapeutics was founded in 2004.

  • Where is ZyStor Therapeutics headquartered?

    ZyStor Therapeutics is headquartered in Wauwatosa, WI.

  • What is the size of ZyStor Therapeutics?

    ZyStor Therapeutics has 9 total employees.

  • What industry is ZyStor Therapeutics in?

    ZyStor Therapeutics’s primary industry is Biotechnology.

  • Is ZyStor Therapeutics a private or public company?

    ZyStor Therapeutics is a Private company.

  • What is the current valuation of ZyStor Therapeutics?

    The current valuation of ZyStor Therapeutics is .

  • What is ZyStor Therapeutics’s current revenue?

    The current revenue for ZyStor Therapeutics is .

  • How much funding has ZyStor Therapeutics raised over time?

    ZyStor Therapeutics has raised $8.5M.

  • Who are ZyStor Therapeutics’s investors?

    Apjohn Ventures, Hexagon (Denver), Keane D'Souza Venture Capital, Mason Wells, and Prolog Ventures are 5 of 9 investors who have invested in ZyStor Therapeutics.

  • When was ZyStor Therapeutics acquired?

    ZyStor Therapeutics was acquired on 17-Aug-2010.

  • Who acquired ZyStor Therapeutics?

    ZyStor Therapeutics was acquired by BioMarin Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »